OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer

Summary by AI BETAClose X

OKYO Pharma has appointed Robert J. Dempsey as Chief Executive Officer, effective immediately, with Gary S. Jacob transitioning to Chief Development Officer and remaining on the Board. Dempsey brings over two decades of ophthalmology experience, including leading the commercialization of Xiidra®, which had a $3.4 billion upfront sale to Novartis, and overseeing Restasis®. This leadership change aims to accelerate the development of urcosimod for neuropathic corneal pain and other inflammatory eye diseases, with a new Phase 2 trial planned for Q1 2026.

Disclaimer*

UK 100

Latest directors dealings